Photo Gallery

Login

Search

News & Updation

  • WJPPS JANUARY ISSUE PUBLISHED
  • JANUARY 2019 Issue has been successfully launched on 1 January 2019

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.647 to 7.421 due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  

Abstract

IN-VITRO EVALUATION OF ANTI-UROLITHIASIS POTENTIAL OF NOVEL SIDDHA FORMULATION PANCHA LAVANA PARPAM USING STRUVITE CRYSTAL GROWTH INHIBITION ASSAY

Dr. J. Nisha*, N. J. Muthu Kumar, S. Visweswaran, N. Anbu and V. Banumathi

ABSTRACT

Urolithiasis is a clinical condition characterized by formation of stones in the urinary tract that causes variable degrees of pain, bleeding, and leads to secondary infection The worldwide occurrence of urolithiasis is increasing and calcium oxalate (CaOx) is the primary constituent of the majority of stones formed in the urinary system of patients reported with urolithiasis. Research focus on drug development towards urolithiasis majorly relies on prevention of crystal aggregates which may tend to become stone later. Crystal growth occurs after supersaturation and then primary nucleus of kidney stone was formed. Crystal aggregation is affected by viscous bindings, such as external crystalline compounds with multiple binding sites. Siddha system of medicine had range of formulation in particular with parpam that can tend to be having higher penetration and also possess significant activity in preventing crystal aggregation. Pancha lavana parpam (PLP) is a novel siddha made of salts and indigenous herbal juices. Present investigation aimed at evaluating the anti-urolithiasis potential of the formulation PLP by struvite crystal growth inhibition assay at two dose level of 0.5% and 1%. The potency of the formulation PLP was critically evaluated by comparing the crystal size of drug treated medium with that of the control gel medium. Average size of the crystal was higher in the control medium with the length of 1.92 ± 0.35 cm and the size of the crystal was significantly decreased in medium contains 0.5% and 1 % of test drug PLP with the average length of 1.24 ± 0.11and 0.96 ± 0.14cm respectively. From the result of the present study it was clealry evident that the siddha formulation PLP has significant anti-urolithiasis property in the tested Invitro medium and may correlated clinically with proper preclinical studies.

Keywords: Siddha system, Urolithiasis, Pancha lavana parpam, Crystal growth, Kidney.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More